SecBot SecBot
8-K ·Filed Mar 19, 2026

MRKR

Marker Therapeutics, Inc.
MIXED
Impact 6/10
Horizonmonths Processed8mo ago SEC0001104659-26-031309
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

Monitor upcoming APOLLO study data in Q2 2026 and the initiation of the company-sponsored pancreatic cancer program, which could serve as key catalysts. The reduced R&D spend despite advancing multiple programs suggests improved efficiency, but the increasing net loss warrants attention to future funding needs.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$1.32
T+0 close · Mar 19, 2026 · via day close
Latest settled
+4.55%
T+60 · $1.38
Vs SPY
−9.80%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 19 $1.32entry
  2. T+1 · 8mo ago +1.52%α +3.26% · $1.34
  3. T+5 · 8mo ago +2.27%α +4.48% · $1.35
  4. T+20 · 7mo ago +25.76%α +18.14% · $1.66
  5. T+60 · 5mo ago +4.55%α −9.80% · $1.38
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Marker Therapeutics reported its 2025 financial results and provided clinical updates, highlighting a 66% objective response rate in relapsed non-Hodgkin lymphoma from its APOLLO study and promising pancreatic cancer research published in Nature Medicine. The company ended 2025 with $17 million in cash, sufficient to fund operations through Q4 2026, while R&D expenses decreased to $11.8 million. The stock has a market cap of $22 million.

Key Financial Metrics

Revenue
$3.5M
-46.2% YoY
EPS
$-0.79

Key Facts

  • 66% objective response rate (8/12 patients) in relapsed non-Hodgkin lymphoma with MT-601 therapy, including 50% complete responses
  • 78% objective response rate (7/9 patients) in Hodgkin lymphoma
  • Nature Medicine publication showed up to 84.6% disease control rate in pancreatic cancer when combined with chemotherapy
  • Cash position of $17 million at year-end 2025, expected to fund operations through Q4 2026
  • R&D expenses decreased to $11.8 million in 2025 from $13.5 million in 2024
  • Net loss increased to $12.2 million in 2025 from $10.7 million in 2024

Financial Impact

Net loss increased by $1.5 million year-over-year while R&D spending decreased by $1.7 million, with cash burn of $12.0 million from operations

cashr&d expensesnet loss

Risk Factors

  • Clinical trial results are from small patient cohorts (8-12 patients) and may not be reproducible in larger studies
  • Company has limited cash runway with funding expected only through Q4 2026, raising potential dilution risk
  • Increased net loss despite lower R&D expenses indicates ongoing financial pressure

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-031309
Document: tm268941d1_8k.htm0001104659-26-031309
Document: 0001104659-26-031309-index-headers.html0001104659-26-031309
Document: 0001104659-26-031309-index.html0001104659-26-031309
Document: 0001104659-26-031309.txt0001104659-26-031309

Track record

5 reports on MRKR

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Oct 19, 202628d ago 8-K Bullish 5/10 Entry $1.20 to $0.8700 Now $0.8300 −30.83% ▼ −27.50% −24.04% vs SPY
  2. Oct 19, 202628d ago Press Release Bullish 5/10 Entry $1.20 to $0.8286 Now $0.8300 −30.83% ▼ −30.95% −27.49% vs SPY
  3. Mar 20, 202634w ago DEFA14A Neutral 4/10 Entry $1.31 to $1.56 Now $0.8300 −36.64% ▲ +19.08% +11.66% vs SPY
  4. Mar 19, 202634w ago 8-K Mixed 6/10 Viewing Entry $1.32 to $1.66 Now $0.8300 −37.12% ▲ +25.76% +18.14% vs SPY
  5. Mar 18, 202634w ago Press Release Mixed 6/10 Entry $1.32 to $1.66 Now $0.8300 −37.12% ▲ +25.76% +18.14% vs SPY
Showing 5 of 5

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 19, 2026